Biotage AB (publ)

Stockholm Stock Exchange BIOT.ST

Biotage AB (publ) Return on Equity (ROE) for the year ending December 31, 2023: 6.73%

Biotage AB (publ) Return on Equity (ROE) is 6.73% for the year ending December 31, 2023, a -58.91% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Biotage AB (publ) Return on Equity (ROE) for the year ending December 31, 2022 was 16.37%, a 9.57% change year over year.
  • Biotage AB (publ) Return on Equity (ROE) for the year ending December 31, 2021 was 14.94%, a -15.47% change year over year.
  • Biotage AB (publ) Return on Equity (ROE) for the year ending December 31, 2020 was 17.68%, a -17.16% change year over year.
  • Biotage AB (publ) Return on Equity (ROE) for the year ending December 31, 2019 was 21.34%, a -10.61% change year over year.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
Loading...
SV Wall Street
Stockholm Stock Exchange: BIOT.ST

Biotage AB (publ)

Description

Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and government authorities and academic institutions, as well as clinical, forensic, and academic laboratories. It operates in 70 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.

Similar companies

ALIF-B.ST

AddLife AB (publ)

USD 13.28

-2.29%

VITR.ST

Vitrolife AB (publ)

USD 19.80

-1.20%

SECT-B.ST

Sectra AB (publ)

USD 22.49

-1.31%

CEVI.ST

CellaVision AB (publ)

USD 19.20

-5.48%

BIOG-B.ST

BioGaia AB (publ)

USD 10.71

-1.60%

StockViz Staff

February 4, 2025

Any question? Send us an email